CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) – Pipeline Review, H1 2018’, provides in depth analysis on CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Central Nervous System and Infectious Disease under development targeting CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)

– The report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects

– The report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

DNAtrix Inc

eTheRNA Immunotherapies NV

Mologen AG

Sanofi

TILT Biotherapeutics Ltd

UCB SA

XL-protein GmbH

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Overview

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Companies Involved in Therapeutics Development

DNAtrix Inc

eTheRNA Immunotherapies NV

Mologen AG

Sanofi

TILT Biotherapeutics Ltd

UCB SA

XL-protein GmbH

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Drug Profiles

AT-1501 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dapirolizumab pegol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Delta-24-RGDOX Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dendritic Cell Therapy + TILT-234 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ECI-006 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target CD40 Ligand for Malignant Melanoma and Bladder Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis B vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INX-021 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISF-35 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LOAd-700 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGN-1601 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NJA-730 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TDI-28 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CD40L and GM-CSF for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIB-4920 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-050 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Dormant Products

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Product Development Milestones

Featured News & Press Releases

Jun 30, 2017: etherna Advances in-vivo MRNA Cancer Immunotherapy Into First Oncology Clinical Studies

Jun 08, 2016: UCB presents Phase 1 results for dapirolizumab pegol at the Annual European Congress of Rheumatology (EULAR 2016)

Nov 17, 2015: Memgen Announces Preclinical Results for ISF35 in Combination with Checkpoint Inhibitors in a Model of Metastatic Melanoma

Sep 16, 2015: MOLOGEN is presenting poster on MGN1601 at International Cancer Immunotherapy Conference

Sep 18, 2014: MOLOGEN Presents Poster Presentations of MGN1601 at ESMO 2014 Congress

May 07, 2014: MOLOGEN: Immunological data on renal cancer therapy MGN1601 presented at CIMT

Feb 03, 2014: MOLOGEN: Final results from renal cancer trial with MGN1601 presented at ASCO Genitourinary Cancers Symposium

Oct 01, 2012: Mologen Presents Updated Data On Renal Cancer Therapy MGN1601 At European Society For Medical Oncology 2012

Mar 30, 2012: MOLOGEN Announces Treatment With Renal Cancer Therapy MGN1601 Generates Clear Survival Benefit For Patients

Feb 21, 2012: MOLOGEN Wins Patent Protection In Japan For Cell-Based Cancer Therapy MGN1601

Dec 19, 2011: ALS Therapy Development Institute Announces Research Agreement With Biogen Idec And UCB To Investigate Role Of CD40L In ALS

Dec 07, 2011: Memgen Announces Upcoming Presentation For ISF35 In Chronic Lymphocytic Leukemia At 2011 ASH Annual Meeting

Nov 21, 2011: MOLOGEN Attains Goals Of Renal Cancer Study With MGN1601 Ahead Of Schedule

Nov 21, 2011: MOLOGEN Attains Goals Of Renal Cancer Study With MGN1601 Ahead Of Schedule

Aug 29, 2011: MOLOGEN Publishes First Results From Phase I/II Clinical Trial With Cell-Based Renal Cancer Therapy MGN1601

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by DNAtrix Inc, H1 2018

Pipeline by eTheRNA Immunotherapies NV, H1 2018

Pipeline by Mologen AG, H1 2018

Pipeline by Sanofi, H1 2018

Pipeline by TILT Biotherapeutics Ltd, H1 2018

Pipeline by UCB SA, H1 2018

Pipeline by XL-protein GmbH, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports